Anti-CD19 CAR-T Cell Therapy for Patients With Refractory Systemic Lupus Erythematosus
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: CAR T cells chimeric antigen receptor cells.
- Who it may be relevant to
- Registry conditions: System Lupus Erythematosus(SLE). Basic parameters: 18 years — 70 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Belarus
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by B-cell dysfunction leading to the production of autoantibodies that play a key role in the onset and progression of the disease. In the treatment of SLE today, glucocorticosteroid hormones, cytostatics (azathioprine, cyclophosphamide, mycophenolate mofetil, hydroxychloroquine, etc.), and biological therapy (rituximab, belimumab) are widely used. However, this therapy has limitations: firstly, it does not always control the autoimmune process and, secondly, it has side effects. Recent global data on the use of CAR T cells in patients with SLE show promising results, including rapid and durable remission, without the need for disease-modifying drugs and glucocorticoids. The use of the so-called academic CAR-T cell products can improve availability and affordability of this therapy option. The aim of this clinical study is to evaluate the efficacy and safety of academic CAR-T cells in refractory SLE patients.
Interventions
- Biological CAR T cells chimeric antigen receptor cells
academical CAR-T product was manufactured using lentiviral vector encoding anti-CD19 CAR.
Primary outcome measures
- SELENA-SLEDAI activity index assessment and serologic remission (defined as normal level of primary (dsDNA and/or antiSm) and antiphospholipid antibodies (lupus anticoagulant (LA), AT to cardiolipinanti-dsDNA and normal complement C3 and C4 levels) [Time frame: 36 months after CAR-T cells infusion]
Secondary outcome measures (1)
- Evaluation of CAR T-Cell-Related Toxicities [Time frame: Start from 0 day up to 30 days after CAR-T cells infusion]
Eligibility criteria
Inclusion criteria
- A confirmed diagnosis of SLE according to the 2019 EULAR/ACR criteria.
- Subacute or acute SLE.
- SLE activity according to the SELENA-SLEDAI disease activity index screening score ≥6 and/or the requirement for prednisolone (or equivalent doses of methylprednisolone) at a dose greater than 7.5 mg/day (6 mg/day for methylprednisolone) to maintain lower disease activity.
- A history of two or more prior therapies (one of the drugs mycophenolate mofetil or cyclophosphamide, or the development of side effects/intolerance to these drugs).
- Patients aged 18 years or older.
- A medical consultation on the need for this treatment method using cell therapy.
- Written informed consent from the patient for treatment.
- Patient compliance with the treatment protocol.
- Adequate organ function.
Exclusion criteria
- Any change in therapy within 90 days prior to the planned administration of CAR-T cell therapy.
- Patient requiring renal replacement therapy.
- Active hepatitis B or active hepatitis C (HCV RNA positive).
- HIV-infected patients.
- Uncontrolled acute life-threatening bacterial, viral, or fungal infection (e.g., positive blood culture ≤ 72 hours before infusion).
- Unstable angina and/or myocardial infarction within 6 months prior to screening.
- Previous or concomitant malignancy with the exception of:
- basal cell or squamous cell carcinoma (adequate wound healing is required before study entry);
- In situ carcinoma of the cervix or breast, without evidence of recurrence for at least 3 years prior to study entry;
- A primary malignant tumor that has been completely resected and in complete remission for ≥ 5 years.
- Pregnant and lactating women.
- Intolerance to the excipients of the cell product.
- Cardiac arrhythmia not controlled by medical therapy.
- Patients with active neurological autoimmune or inflammatory disorders (e.g., Guillain-Barré syndrome, amyotrophic lateral sclerosis).
- The presence of any primary immunodeficiency.
- Socioeconomic or geographic circumstances that cannot guarantee adequate compliance with the protocol requirements for treatment and follow-up.
\-
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Belarus · 1 center
- NN Alexandrov National Cancer Centre of Belarus — Lyasny
Identifiers
NCT: NCT07720310 · 20251677